Breakpoints: current practice and future perspectives (Q40644153)

22 September 2017

title

Breakpoints: current practice and future perspectives (English)

1 reference

22 September 2017

Johan W Mouton

1

1 reference

22 September 2017

publication date

1 April 2002

1 reference

International Journal of Antimicrobial Agents

22 September 2017

published in

1 reference

22 September 2017

volume

19

1 reference

22 September 2017

issue

4

1 reference

22 September 2017

page(s)

323-331

1 reference

History and development of antimicrobial susceptibility testing methodology.

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Determination of minimum inhibitory concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamics of fluoroquinolones in experimental models of endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

Modeling approach to diameter breakpoint determination.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900028-6

7 January 2021

10.1016/S0924-8579(02)00028-6

Identifiers

DOI

1 reference

22 September 2017

1 reference